Bernard Poussot Elected CEO of Wyeth

Article

Wyeth (Madison, NJ) has elected Bernard Poussot president and chief executive officer (CEO), effective January 1, 2008.

Wyeth (Madison, NJ) has elected Bernard Poussot president and chief executive officer (CEO), effective January 1, 2008. Poussot began his career at Wyeth in 1986. In April 2006, Poussot was promoted to president and vice chairman of Wyeth, and in January 2007, he was promoted to president, chief operating officer, and vice chairman. Robert Essner, current chairman and CEO, will continue as chairman of the board of directors after his term as CEO ends at the end of 2007.

Wyeth’s release

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides

Feliza Mirasol
April 18th 2025
Article

Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Cellino Partners with Karis Bio for Autologous iPSC Therapy to Treat Cardiovascular Disease

Feliza Mirasol
April 18th 2025
Article

This collaboration aims to advance a first-in-human clinical study by using autologous iPSC technology.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza Partners with Ethris to Develop Spray-Dried mRNA Vaccines for Preventing Respiratory Disease

Feliza Mirasol
April 11th 2025
Article

The spray-dried formulations for Ethris’ mRNA vaccine candidates will be developed at Lonza’s Bend, Ore., Center of Excellence in accordance with GMP standards.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Entos Collaborates with Circio to Develop In-Vivo Delivery of DNA Vectors

Feliza Mirasol
April 10th 2025
Article

Through this collaboration, Circio will combine its circVec DNA vectors with Entos’ Fusogenix PLV delivery technology, which is expected to enhance delivery efficiency and reduce toxicity.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Enosium Life Science Acquires Rweality in Strategic Transaction

Feliza Mirasol
April 9th 2025
Article

The acquisition of Rweality will strengthen Enosium Life Science’s market access and medical-economic development strategies.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Sai Life Sciences Establishes Peptide Research Center at R&D Campus in India

Feliza Mirasol
April 7th 2025
Article

Rising demand for peptide-based therapeutics prompts the launch of this new peptide research center, which will offer services across peptide synthesis, discovery, and advanced modalities.

© 2025 MJH Life Sciences

All rights reserved.